-
公开(公告)号：US20150132324A1
公开(公告)日：2015-05-14
申请号：US14605549
申请日：2015-01-26
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang CONG , Heng Cheng , Sanjeev Gangwar
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
Abstract translation: 其中R 1，R 2，R 3a，R 3b，R 4，R 5，W和n如本文所定义的式（I）的调节素化合物是可用于治疗癌症的抗有丝分裂剂，特别是当与 靶向部分。
-
![1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS](/abs-image/US/2023/05/04/US20230140430A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230140430A1
公开(公告)日：2023-05-04
申请号：US17792887
申请日：2021-01-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Matthew COX , Liqi HE , Sanjeev GANGWAR , Ashvinikumar V. GAVAI , Matthias BROEKEMA , Qiang CONG , Daniel O'MALLEY , Yam B. POUDEL , Christine M. TARBY
IPC: C07D519/00 , A61K45/06
Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
-
![C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS](/abs-image/US/2023/04/27/US20230127326A1/abs.jpg.150x150.jpg)
3.发明申请公开(公告)号：US20230127326A1
公开(公告)日：2023-04-27
申请号：US17792905
申请日：2021-01-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Christine M. TARBY , Qiang CONG , Ashvinikumar V. GAVAI , Sanjeev GANGWAR , Matthias BROEKEMA , Patrice GILL , Prasanna SIVAPRAKASAM , Walter L. JOHNSON , Murugaiah Andappan Murugaiah SUBBAIAH , Yam B. POUDEL
IPC: A61K31/519 , A61K39/395 , C07D487/04
Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
-
公开(公告)号：US20170326247A1
公开(公告)日：2017-11-16
申请号：US15587927
申请日：2017-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Qiang CONG , Sanjeev GANGWAR , Vangipuram S. RANGAN , Mei-Chen SUNG
CPC classification number: A61K47/6803 , A61K47/6811 , A61K47/6851 , C07K16/28 , C07K2317/565 , C07K2317/94
Abstract: The drug component of an antibody-drug conjugate having a structure according to formula (II), where Ab, m, n, R1, R2, R3, R4, and R5 are as defined in the application, exhibits unexpectedly improved stability.
-
![1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS](/abs-image/US/2023/05/11/US20230144824A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230144824A1
公开(公告)日：2023-05-11
申请号：US17793248
申请日：2021-01-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Liqi HE , Ashvinikumar V. GAVAI , Sanjeev GANGWAR , Qiang CONG , Yam B. POUDEL , Prasanna SIVAPRAKASAM , Christine M. TARBY , Patrice GILL , Andrew F. DONNELL , Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
-
Patent Agency Ranking
![1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS](/abs-image/US/2023/04/27/US20230130516A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230130516A1
公开(公告)日：2023-04-27
申请号：US17792878
申请日：2021-01-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Qian ZHANG , Sanjeev GANGWAR , Ashvinikumar V. GAVAI , Qiang CONG , Yam B. POUDEL , Liqi HE , Prasanna SIVAPRAKASAM , Christine M. TARBY
IPC: A61K31/519 , C07D487/04 , C07D519/00 , A61K31/5377 , A61K39/395
Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
-
公开(公告)号：US20160264624A1
公开(公告)日：2016-09-15
申请号：US15171592
申请日：2016-06-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Qiang CONG , Heng Cheng , Sanjeev Gangwar
IPC: C07K5/117
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
Abstract translation: 其中R1，R2 R3a，R3b，R4，R5，W和n如本文所定义，是可用于治疗癌症的抗有丝分裂剂，特别是当与靶向部分缀合时。
-
公开(公告)号：US20140227298A1
公开(公告)日：2014-08-14
申请号：US14177498
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang CONG , Heng CHENG , Sanjeev GANGWAR
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
Abstract translation: 其中R 1，R 2 R 3 a，R 3b，R 4，R 5，W和n如本文所定义的式（I）的调蛋白素化合物是可用于治疗癌症的抗有丝分裂剂，特别是当与靶向部分缀合时 。
-
9.发明申请公开(公告)号：US20170326249A1
公开(公告)日：2017-11-16
申请号：US15587963
申请日：2017-05-05
Applicant: Bristol-Myers Squibb Company
Inventor： Chin PAN , Josephine M. CARDARELLI , Haichun HUANG , Sanjeev GANGWAR , Qiang CONG , Karla A. HENNING , Chetana RAO-NAIK , Mohan SRINIVASAN , Vangipuram S. RANGAN , Francis Y. LEE , Ginger C. RAKESTRAW
CPC classification number: A61K47/6829 , A61K9/0019 , A61K47/6803 , A61K47/6849 , A61K47/6853 , C07K5/0205 , C07K16/303 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: An antibody-drug conjugate having a structure represented by formula (I) wherein m is 1, 2, 3, or 4 and Ab is an anti-glypican-3 antibody having heavy and light chain CDRs as disclosed herein.
-
公开(公告)号：US20170260232A1
公开(公告)日：2017-09-14
申请号：US15602156
申请日：2017-05-23
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang CONG , Heng CHENG , Sanjeev GANGWAR
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/64 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
